Genfit Stock (NASDAQ:GNFT)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$5.97

52W Range

$3.08 - $6.42

50D Avg

$5.09

200D Avg

$4.25

Market Cap

$286.89M

Avg Vol (3M)

$13.67K

Beta

1.09

Div Yield

-

GNFT Company Profile


Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

FR

Employees

169

IPO Date

Mar 27, 2019

Website

GNFT Performance


GNFT Financial Summary


Dec 23Dec 22Dec 21
Revenue€28.57M€20.20M€80.07M
Operating Income€-36.55M€-27.55M€76.74M
Net Income€-28.89M€-23.72M€67.26M
EBITDA€-34.90M€-17.26M€79.48M
Basic EPS€-0.58€-0.48€1.50
Diluted EPS€-0.58€-0.48€1.21

Fiscal year ends in Dec 23 | Currency in EUR

Latest Earnings Call Transcripts


Q4 21Apr 08, 22 | 10:24 AM
Q2 20Sep 30, 20 | 9:49 PM

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
FENCFennec Pharmaceuticals Inc.
CSBRChampions Oncology, Inc.
ERYPPHAXIAM Therapeutics S.A.
JANXJanux Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
KROSKeros Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.
HCWBHCW Biologics Inc.
MNOVMediciNova, Inc.
RZLTRezolute, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG
ELYMEliem Therapeutics, Inc.